# Panitumumab Skin Toxicity Prevention Trial

> **NCT03167268** · PHASE2 · UNKNOWN · sponsor: **Ospedale San Carlo Borromeo** · enrollment: 28 (actual)

## Conditions studied

- Colorectal Cancer Metastatic
- Skin Toxicity

## Interventions

- **DRUG:** Lycopene
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03167268
- **Lead sponsor:** Ospedale San Carlo Borromeo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08-03
- **Primary completion:** 2020-01-13
- **Final completion:** 2021-11-30
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03167268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03167268, "Panitumumab Skin Toxicity Prevention Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03167268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*